GlassScriptPhysician profile
Guangchen Zou
NPI 1093378994
$873.36
in general payments reported to CMS, 2019-2025
11 companies · $211 in 2025
The $211 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $662 · 2025: $211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $850 · Education: $23.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $849.94 |
| Education | $23.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $130.71 | 2024-2025 | Lokelma, Farxiga |
| Genzyme Corporation | $126.43 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.99 | 2024 | |
| Merck Sharp & Dohme LLC | $122.77 | 2024 | Winrevair |
| Glaxosmithkline, LLC. | $121.81 | 2024 | Benlysta |
| Travere Therapeutics, INC. | $106.18 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $41.93 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.90 | 2025 | Jardiance |
| Calliditas Therapeutics US INC. | $23.90 | 2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $22.99 | 2025 | Jynarque |
| Akebia Therapeutics INC | $14.75 | 2025 | Vafseo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guangchen Zou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.